Anthropometric and biochemical assessment of schizophrenic patients taking clozapine
Keywords:
Clozapine, Schizophrenia, ObesityAbstract
Objective
The objective was to access the overweight/obesity rates and variations of biochemical blood parameters in male schizophrenic outpatients taking antipsychotic medication (clozapine), treated at the Schizophrenia and Dementia First Aid Station of the Clinics Hospital in Porto Alegre.
Methods
This is a cross-sectional study with 40 male outpatients diagnosed with schizophrenia and taking clozapine, from the Clinics Hospital in Porto Alegre. Associations between body mass index, waist circumference, body fat percentage, lipid levels and fasting glucose and medication dosage, diet therapy and clozapine monotherapy were verified.
Results
There was a rate of 71.8% of overweight/obesity, 76.9% of increased waist circumference and 94.1% of high body fat percentage. More than half of the patients (56.8%) had low density lipoprotein cholesterol levels above normal and 64.1% had high triglycerides. LDL-cholesterol levels increased with increasing clozapine dose (p=0.01).
Conclusion
Patients on clozapine presented excess weight and significant lipid abnormality, needing frequent monitoring of the biochemical blood parameters and early nutritional intervention to optimize treatment.
Downloads
References
Manual Diagnóstico e Estatístico de Transtornos Mentais - DSM-IV-TR. 4a. ed. Porto Alegre: Artmed; 2003.
Organização Mundial da Saúde. Classificação de transtornos mentais e de comportamento da CID-10: descrições clínicas e diretrizes diagnósticas. Porto Alegre: Artmed; 1993.
Mari JJ, Leitão RJ. A epidemiologia da esquizofrenia. Rev Bras Psiquiatr. 2000; 22(1):15-7. doi: 10.1590/S1516-44462000000500006.
Rang HP, Dale MM, Ritter JM, Moore PK. Farmacologia. 5a. ed. Rio de Janeiro: Elsevier; 2004.
Kaplan HI. Compêndio de psiquiatria: ciências do comportamento e psiquiatria clínica. 7a. ed. Porto Alegre: Artmed; 1997.
Chaves AC. Diferenças entre os sexos na esquizofrenia. Rev Bras Psiquiatr. 2000; 22(1):21-2. doi: 10.1590/S1516-44462000000500008.
Gama CS, Souza CM, Lobato MI, Abreu PSB. Clozapine use report in 56 patients seen by Clerkship of Health and Environment of the State of Rio Grande do Sul’s Program of Attention to the Refractory Schizophrenia. Rev Psiquiatr Rio Grande Sul. 2004; 26(1):21-8. doi: 10.1590/S0101-81082004000100004.
Morais RMO, Oliveira IR. Antipsicóticos. In: Silva P. Farmacologia. 7a. ed. Rio de Janeiro: Guanabara Koogan; 2006.
Casey DE. Dyslipidemia and atypical antipsychotis drugs. J Clin Psychiatry. 2004; 65(18):27-35.
Lewis SW, Barnes TRE, Davies L, Murray RM, Dunn G, Hayhurst KP, et al. Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia. Schizophr Bull. 2006; 32(4): 715-23.
Meltzer, HY. Putting metabolic side effects into perspective: risks versus benefits of atypical antipsychotics. J Clin Psychiatry. 2001; 62(27):35-9.
Munoz P, Gallardo R. Transtornos metabólicos en pacientes esquizofrênicos tratados con clozapina. Rev Chil de Neuro-Psiquiatr. 2004; 42(1):37-42. doi: 10.4067/S0717-92272004000100005.
Brasil. I Diretriz Brasileira de Diagnóstico e Tratamento da Síndrome Metabólica. Arq Bras Cardiol. 2005; 84(1):3-28. doi: 10.1590/S0066-782X2005000700001.
Duncan BB, Schmidt MI. Chronic activation of the innate immune system may underlie the metabolic syndrome. São Paulo J Med. 2001; 119(3):122-7. doi:.10.1590/S1516-31802001000300008.
Goff DC, Cather C, Evins AE, Henderson DC, Freudenreich O, Copeland PM, et al. Medical morbidity and mortality in Schizophrenia: guidelines for psychiatrists. J Clin Psychiatry. 2005; 66(2):183-93.
World Health Organization. Physical status: the use and interpretation of anthropometry. Genebra: WHO; 1998.
Brasil. IV Diretriz Brasileira Sobre as Dislipidemias e Prevenção da Aterosclerose do Departamento de Aterosclerose da Sociedade Brasileira de Cardiologia. Arq Bras Cardiol. 2007; 88(1)2-19. doi:.10.1590/S0066-782X2007000700002.
Lohman TG. Advances in body composition assessment. Current issues in exercise science series. Monografh n.3. Champaign (IL): Human Kinetics; 1992.
Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP). Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285(19): 2486-97.
American Diabetes Association. Standards of medical care in diabetes. Diabetes Care. 2005; 28(1):4-36.
Brasil. Ministério da Saúde. Guia alimentar para a população brasileira: promovendo a alimentação saudável. Brasília; 2006.
Souza VBN, Guedes ARA. Índice de massa corpórea de esquizofrênicos em uso de antipsicóticos típicos e atípicos. Neurobiologia. 2002; 65(1):77-80.
Henderson DC, Cagliero E, Gray C, Nasrallah RA, Hayden DL, Schoenfeld DA, et al. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: a five-year naturalistic study. Am J Psychiatry. 2000; 157(6):975-81.
Cercato C, Mancini MC, Arguello AMC, Passos VQ, Villares SMF, Halpern A. Systemic hypertension, diabetes mellitus, and dyslipidemia in relation to body mass index: evaluation of a Brazilian population. Rev Hosp Clin. 2004; 59(3):113-8. doi: 10.1590/S0041-87812004000300004.
Bustillo JR, Buchanan Robert W, Irish D, Breier A. Differential effect of Clozapine on weight: a controlled study. Am J Psychiatry.1996; 153(6): 817-9.
Allison DB, Mentore JL, Ed MS, Heo M, Chandler LP, Cappelleri JC, et al. Antipsychotics-induced weight-gain: a comprehensive research synthesis. Am J Psychiatry. 1999; 156(11):1686-9.
Teixeira PJR, Rocha FL. Efeitos adversos metabólicos de antipsicóticos e estabilizadores de humor. Rev Psiquiatr Rio Grande do Sul. 2006; 28(2):186-96. doi: 10.1590/S0101-81082006000200011.
Kivircik BB, Alptekin K, Çaliskan S, Çomlejçi A, Oruk G, Tumuklu M, et al. Effect of clozapine on serum leptin, insulin levels, and body weight and composition in patients with schizophrenia. Prog Neuro-Psychopharmacol Biol Psychiatry. 2003; 27(5):795-9.
Wu MK, Huang CY, Liou YJ, Wang CK, Lee SD. Glucose-insulin homeostasis, lipid profiles and GH-IGF-IGFBP axis in clozapine-treated schizophrenic obesity versus non-psychiatric obesity. Int J Obes. 2008; 32(3):436-42. doi:10.1038/sj.ijo.0803750.
Leon, J, Diaz FJ, Josiassen RC, Cooper TB, Simpson GM. Weight gain during a double-blind multidosage Clozapine study. J Clin Psychopharmacol. 2007; 27(1):22-7.
Baymiller SP, Ball P, McMahon RP, Buchanan RW. Serum glucose and lipid changes during the course of clozapine treatment: the effect of concurrent beta-adrenergic antagonist treatment. Schizophr Res. 2003; 59(1):49-57.
De Hert, M, Peuskens B, Winkel RV, Kalnicka D, Hanssens L, Eyck DV, et al. Body weight and selfesteem in patients with schizophrenia evaluated with B-WISE®. Schizophr Res. 2006; 88(1-3): 222-6.
McIntyre RS. Mechanisms of antipsychotic-induced weight gain. J Clin Psychiatry. 2001; 62(23):23-9.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Karine ZORTÉA, Patrícia Martins BOCK, Dolores Benites MORENO, Paulo Silva Belmonte de ABREU
This work is licensed under a Creative Commons Attribution 4.0 International License.
